Symbols / COCP $1.50 -0.66% Cocrystal Pharma, Inc.
COCP Chart
About
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 20.68M |
| Enterprise Value | 15.30M | Income | -8.83M | Sales | — |
| Book/sh | 0.46 | Cash/sh | 0.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -1.55 | PEG | — |
| P/S | — | P/B | 3.27 | P/C | — |
| EV/EBITDA | -1.71 | EV/Sales | — | Quick Ratio | 3.50 |
| Current Ratio | 3.68 | Debt/Eq | 23.77 | LT Debt/Eq | — |
| EPS (ttm) | -0.78 | EPS next Y | -0.97 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 08:00 | ROA | -48.66% |
| ROE | -111.40% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 13.79M |
| Shs Float | 9.12M | Short Float | 1.88% | Short Ratio | 5.41 |
| Short Interest | — | 52W High | 2.67 | 52W Low | 0.86 |
| Beta | — | Avg Volume | 2.35M | Volume | 4.16M |
| Target Price | $6.67 | Recom | None | Prev Close | $1.51 |
| Price | $1.50 | Change | -0.66% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-06-20 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-01-03 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-12-04 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-10-04 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-06-02 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-05-24 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-01-24 | main | HC Wainwright & Co. | — → Buy | $35 |
| 2022-11-07 | main | HC Wainwright & Co. | — → Buy | $42 |
- Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history - Yahoo Finance UK Sun, 05 Apr 2026 14
- Why Cocrystal Pharma Shares Are Cooling Off Monday? - benzinga.com Mon, 06 Apr 2026 13
- $COCP stock is up 39% today. Here's what we see in our data. - Quiver Quantitative hu, 02 Apr 2026 15
- COCP Stock Soars 75% — What Is The Link To Cocrystal’s Norovirus Treatment? - Stocktwits hu, 02 Apr 2026 13
- Cocrystal's norovirus pill gets FDA fast track amid 685M yearly cases - Stock Titan hu, 02 Apr 2026 12
- COCP Stock Price, Quote & Chart | COCRYSTAL PHARMA INC (NASDAQ:COCP) - ChartMill hu, 02 Apr 2026 07
- Shares +48% after hours: COCP Cocrystal Pharma NASDAQ 03 Apr earnings spotlight - Meyka Fri, 03 Apr 2026 22
- We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - simplywall.st Sat, 04 Apr 2026 13
- Cocrystal Pharma Advances in Norovirus Study as Financial Challenges Loom - StocksToTrade hu, 02 Apr 2026 14
- The Vita Coco Company, Inc. (COCO) stock price, news, quote and history - Yahoo Finance UK Fri, 03 Apr 2026 19
- No approved norovirus drug exists. Cocrystal now tests one in humans - Stock Titan ue, 31 Mar 2026 12
- COCO Stock Price, Quote & Chart | VITA COCO CO INC/THE (NASDAQ:COCO) - ChartMill hu, 02 Apr 2026 07
- FDA Fast Track backs Cocrystal (Nasdaq: COCP) oral norovirus antiviral CDI-988 - Stock Titan hu, 02 Apr 2026 12
- We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - Yahoo Finance Sat, 04 Apr 2026 12
- Cocrystal Pharma (NASDAQ: COCP) cuts 2025 loss to $8.8M and advances antivirals - Stock Titan ue, 31 Mar 2026 12
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
9.02
-49.55%
|
17.88
-15.51%
|
21.16
+16.66%
|
18.14
|
| Research And Development |
|
5.05
-59.68%
|
12.54
-17.35%
|
15.17
+22.41%
|
12.39
|
| Selling General And Administration |
|
3.96
-25.78%
|
5.34
-10.83%
|
5.99
+4.26%
|
5.75
|
| General And Administrative Expense |
|
3.96
-25.78%
|
5.34
-10.83%
|
5.99
+4.26%
|
5.75
|
| Other Gand A |
|
3.96
-25.78%
|
5.34
-10.83%
|
5.99
+4.26%
|
5.75
|
| Total Expenses |
|
9.02
-49.55%
|
17.88
-15.51%
|
21.16
+16.66%
|
18.14
|
| Operating Income |
|
-9.02
+49.55%
|
-17.88
+15.51%
|
-21.16
-16.66%
|
-18.14
|
| Total Operating Income As Reported |
|
-9.02
+49.55%
|
-17.88
+3.67%
|
-18.56
+52.20%
|
-38.83
|
| EBITDA |
|
-8.64
+50.42%
|
-17.43
+17.61%
|
-21.16
-19.21%
|
-17.75
|
| Normalized EBITDA |
|
-8.70
+49.64%
|
-17.27
+27.12%
|
-23.69
-903.46%
|
2.95
|
| Reconciled Depreciation |
|
0.38
-15.70%
|
0.45
+132.13%
|
-1.39
-457.73%
|
0.39
|
| EBIT |
|
-9.02
+49.55%
|
-17.88
+15.51%
|
-21.16
-16.66%
|
-18.14
|
| Total Unusual Items |
|
0.05
+133.13%
|
-0.16
-106.43%
|
2.54
+112.25%
|
-20.70
|
| Total Unusual Items Excluding Goodwill |
|
0.05
+133.13%
|
-0.16
-106.43%
|
2.54
+112.25%
|
-20.70
|
| Special Income Charges |
|
—
|
0.00
-100.00%
|
2.60
+112.57%
|
-20.69
|
| Other Special Charges |
|
—
|
—
|
-2.60
-262.50%
|
1.60
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
-100.00%
|
19.09
|
| Net Income |
|
-8.83
+49.55%
|
-17.50
+2.67%
|
-17.98
+53.69%
|
-38.84
|
| Pretax Income |
|
-8.83
+49.55%
|
-17.50
+2.67%
|
-17.98
+53.69%
|
-38.84
|
| Net Non Operating Interest Income Expense |
|
0.13
-75.05%
|
0.54
-16.09%
|
0.64
+32100.00%
|
-0.00
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
0.13
-75.05%
|
0.54
-16.09%
|
0.64
+32100.00%
|
-0.00
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Other Income Expense |
|
0.05
+133.13%
|
-0.16
-106.43%
|
2.54
+112.25%
|
-20.70
|
| Gain On Sale Of Security |
|
0.05
+133.13%
|
-0.16
-150.77%
|
-0.07
-983.33%
|
-0.01
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.83
+49.55%
|
-17.50
+2.67%
|
-17.98
+53.69%
|
-38.84
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.83
+49.55%
|
-17.50
+2.67%
|
-17.98
+53.69%
|
-38.84
|
| Net Income From Continuing And Discontinued Operation |
|
-8.83
+49.55%
|
-17.50
+2.67%
|
-17.98
+53.69%
|
-38.84
|
| Net Income Continuous Operations |
|
-8.83
+49.55%
|
-17.50
+2.67%
|
-17.98
+53.69%
|
-38.84
|
| Normalized Income |
|
-8.88
+48.76%
|
-17.34
+15.49%
|
-20.52
-13.12%
|
-18.14
|
| Net Income Common Stockholders |
|
-8.83
+49.55%
|
-17.50
+2.67%
|
-17.98
+53.69%
|
-38.84
|
| Diluted EPS |
|
-0.78
+54.65%
|
-1.72
+8.02%
|
-1.87
+60.80%
|
-4.77
|
| Basic EPS |
|
-0.78
+54.65%
|
-1.72
+8.02%
|
-1.87
+60.80%
|
-4.77
|
| Basic Average Shares |
|
11.29
+10.97%
|
10.17
+5.42%
|
9.65
+18.52%
|
8.14
|
| Diluted Average Shares |
|
11.29
+10.97%
|
10.17
+5.42%
|
9.65
+18.52%
|
8.14
|
| Diluted NI Availto Com Stockholders |
|
-8.83
+49.55%
|
-17.50
+2.67%
|
-17.98
+53.69%
|
-38.84
|
| Total Other Finance Cost |
|
-0.13
+75.05%
|
-0.54
+16.09%
|
-0.64
-32100.00%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
9.71
-27.82%
|
13.46
-56.95%
|
31.26
-23.46%
|
40.84
|
| Current Assets |
|
8.13
-29.76%
|
11.58
-60.19%
|
29.09
-27.59%
|
40.18
|
| Cash Cash Equivalents And Short Term Investments |
|
7.03
-28.75%
|
9.86
-62.58%
|
26.35
-29.05%
|
37.14
|
| Cash And Cash Equivalents |
|
7.03
-28.75%
|
9.86
-62.58%
|
26.35
-29.05%
|
37.14
|
| Cash Financial |
|
7.03
-28.75%
|
9.86
-62.58%
|
26.35
-29.05%
|
37.14
|
| Receivables |
|
0.71
-41.89%
|
1.22
+36.52%
|
0.89
+24.30%
|
0.72
|
| Accounts Receivable |
|
—
|
—
|
—
|
—
|
| Taxes Receivable |
|
0.71
-41.89%
|
1.22
+36.52%
|
0.89
+24.30%
|
0.72
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Restricted Cash |
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
+0.00%
|
0.07
|
| Other Current Assets |
|
0.33
-23.72%
|
0.43
-75.75%
|
1.77
-20.95%
|
2.24
|
| Total Non Current Assets |
|
1.58
-15.88%
|
1.88
-13.47%
|
2.17
+227.49%
|
0.66
|
| Net PPE |
|
1.48
-19.71%
|
1.85
-12.96%
|
2.12
+244.48%
|
0.62
|
| Gross PPE |
|
3.48
-7.73%
|
3.78
-3.80%
|
3.92
+76.01%
|
2.23
|
| Accumulated Depreciation |
|
-2.00
-3.73%
|
-1.93
-6.99%
|
-1.80
-11.71%
|
-1.61
|
| Machinery Furniture Equipment |
|
0.15
+0.00%
|
0.15
+0.00%
|
0.15
+18.32%
|
0.13
|
| Other Properties |
|
3.33
-8.06%
|
3.62
-3.95%
|
3.77
+79.61%
|
2.10
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
—
|
0.00
|
| Goodwill |
|
—
|
—
|
—
|
0.00
|
| Non Current Prepaid Assets |
|
0.10
+227.59%
|
0.03
-36.96%
|
0.05
+0.00%
|
0.05
|
| Total Liabilities Net Minority Interest |
|
3.38
-14.04%
|
3.93
-19.32%
|
4.88
+282.95%
|
1.27
|
| Current Liabilities |
|
2.21
-8.98%
|
2.43
-25.57%
|
3.26
+168.26%
|
1.22
|
| Payables And Accrued Expenses |
|
1.79
-10.90%
|
2.01
-31.00%
|
2.91
+244.33%
|
0.85
|
| Payables |
|
0.89
-42.28%
|
1.54
+26.19%
|
1.22
+99.02%
|
0.61
|
| Accounts Payable |
|
0.89
-42.28%
|
1.54
+26.19%
|
1.22
+99.02%
|
0.61
|
| Current Accrued Expenses |
|
0.90
+92.52%
|
0.47
-72.32%
|
1.69
+628.88%
|
0.23
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.09
-27.35%
|
0.12
+7.34%
|
0.11
-16.15%
|
0.13
|
| Current Debt And Capital Lease Obligation |
|
0.33
+10.96%
|
0.30
+25.42%
|
0.24
+0.00%
|
0.24
|
| Current Capital Lease Obligation |
|
0.33
+10.96%
|
0.30
+25.42%
|
0.24
+0.00%
|
0.24
|
| Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
1.17
-22.19%
|
1.50
-6.70%
|
1.61
+2729.82%
|
0.06
|
| Long Term Debt And Capital Lease Obligation |
|
1.17
-22.19%
|
1.50
-6.70%
|
1.61
+2729.82%
|
0.06
|
| Long Term Capital Lease Obligation |
|
1.17
-22.19%
|
1.50
-6.70%
|
1.61
+2729.82%
|
0.06
|
| Stockholders Equity |
|
6.33
-33.52%
|
9.52
-63.91%
|
26.38
-33.32%
|
39.57
|
| Common Stock Equity |
|
6.33
-33.52%
|
9.52
-63.91%
|
26.38
-33.32%
|
39.57
|
| Capital Stock |
|
0.01
+30.00%
|
0.01
+0.00%
|
0.01
+25.00%
|
0.01
|
| Common Stock |
|
0.01
+30.00%
|
0.01
+0.00%
|
0.01
+25.00%
|
0.01
|
| Share Issued |
|
13.78
+35.49%
|
10.17
+0.00%
|
10.17
+24.94%
|
8.14
|
| Ordinary Shares Number |
|
13.78
+35.49%
|
10.17
+0.00%
|
10.17
+24.94%
|
8.14
|
| Additional Paid In Capital |
|
348.57
+1.64%
|
342.93
+0.19%
|
342.29
+1.42%
|
337.49
|
| Retained Earnings |
|
-342.25
-2.65%
|
-333.42
-5.54%
|
-315.91
-6.04%
|
-297.93
|
| Total Equity Gross Minority Interest |
|
6.33
-33.52%
|
9.52
-63.91%
|
26.38
-33.32%
|
39.57
|
| Total Capitalization |
|
6.33
-33.52%
|
9.52
-63.91%
|
26.38
-33.32%
|
39.57
|
| Working Capital |
|
5.92
-35.27%
|
9.15
-64.57%
|
25.83
-33.71%
|
38.96
|
| Invested Capital |
|
6.33
-33.52%
|
9.52
-63.91%
|
26.38
-33.32%
|
39.57
|
| Total Debt |
|
1.50
-16.67%
|
1.81
-2.54%
|
1.85
+523.91%
|
0.30
|
| Capital Lease Obligations |
|
1.50
-16.67%
|
1.81
-2.54%
|
1.85
+523.91%
|
0.30
|
| Net Tangible Assets |
|
6.33
-33.52%
|
9.52
-63.91%
|
26.38
-33.32%
|
39.57
|
| Tangible Book Value |
|
6.33
-33.52%
|
9.52
-63.91%
|
26.38
-33.32%
|
39.57
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.19
+50.31%
|
-16.48
-12.40%
|
-14.67
+31.58%
|
-21.43
|
| Cash Flow From Continuing Operating Activities |
|
-8.19
+50.31%
|
-16.48
-12.40%
|
-14.67
+31.58%
|
-21.43
|
| Net Income From Continuing Operations |
|
-8.83
+49.55%
|
-17.50
+2.67%
|
-17.98
+53.69%
|
-38.84
|
| Depreciation Amortization Depletion |
|
0.38
-15.70%
|
0.45
+132.13%
|
-1.39
-457.73%
|
0.39
|
| Depreciation |
|
0.38
-15.70%
|
0.45
+132.13%
|
-1.39
-457.73%
|
0.39
|
| Depreciation And Amortization |
|
0.38
-15.70%
|
0.45
+132.13%
|
-1.39
-457.73%
|
0.39
|
| Other Non Cash Items |
|
-0.30
-43.33%
|
-0.21
-113.44%
|
1.56
+847.85%
|
-0.21
|
| Stock Based Compensation |
|
0.27
-58.01%
|
0.64
-19.73%
|
0.80
-6.32%
|
0.85
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
-100.00%
|
19.09
|
| Operating Gains Losses |
|
—
|
—
|
—
|
-0.01
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
-0.01
|
| Change In Working Capital |
|
0.29
+110.00%
|
0.14
-94.02%
|
2.34
+186.36%
|
-2.71
|
| Change In Receivables |
|
0.51
+256.62%
|
-0.33
-86.78%
|
-0.17
+75.70%
|
-0.72
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
0.04
-97.35%
|
1.36
+189.36%
|
0.47
+128.06%
|
-1.68
|
| Change In Payables And Accrued Expense |
|
-0.25
+71.96%
|
-0.90
-143.74%
|
2.05
+737.38%
|
-0.32
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
—
|
| Investing Cash Flow |
|
-0.01
-50.00%
|
-0.01
+93.22%
|
-0.12
-59.46%
|
-0.07
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
-50.00%
|
-0.01
+93.22%
|
-0.12
-59.46%
|
-0.07
|
| Net PPE Purchase And Sale |
|
-0.01
-50.00%
|
-0.01
+93.22%
|
-0.12
-59.46%
|
-0.07
|
| Purchase Of PPE |
|
-0.01
-50.00%
|
-0.01
+93.22%
|
-0.12
-59.46%
|
-0.07
|
| Capital Expenditure |
|
-0.01
-50.00%
|
-0.01
+93.22%
|
-0.12
-59.46%
|
-0.07
|
| Financing Cash Flow |
|
5.37
|
0.00
-100.00%
|
3.99
+14888.89%
|
-0.03
|
| Cash Flow From Continuing Financing Activities |
|
5.37
|
0.00
-100.00%
|
3.99
+14888.89%
|
-0.03
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
+100.00%
|
-0.01
+74.07%
|
-0.03
|
| Repayment Of Debt |
|
—
|
0.00
+100.00%
|
-0.01
+74.07%
|
-0.03
|
| Long Term Debt Payments |
|
—
|
0.00
+100.00%
|
-0.01
+74.07%
|
-0.03
|
| Net Long Term Debt Issuance |
|
—
|
0.00
+100.00%
|
-0.01
+74.07%
|
-0.03
|
| Net Common Stock Issuance |
|
5.37
|
0.00
-100.00%
|
4.00
|
0.00
|
| Changes In Cash |
|
-2.83
+82.81%
|
-16.49
-52.84%
|
-10.79
+49.89%
|
-21.54
|
| Beginning Cash Position |
|
9.94
-62.41%
|
26.43
-28.99%
|
37.22
-36.65%
|
58.76
|
| End Cash Position |
|
7.10
-28.54%
|
9.94
-62.41%
|
26.43
-28.99%
|
37.22
|
| Free Cash Flow |
|
-8.20
+50.26%
|
-16.49
-11.56%
|
-14.78
+31.27%
|
-21.51
|
| Common Stock Issuance |
|
5.37
|
0.00
-100.00%
|
4.00
|
0.00
|
| Issuance Of Capital Stock |
|
5.37
|
0.00
-100.00%
|
4.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-02 View
- 10-K2026-03-31 View
- 8-K2026-03-31 View
- 8-K2026-03-13 View
- 8-K2026-03-09 View
- 42026-02-25 View
- 8-K2026-02-19 View
- 42026-02-09 View
- 8-K2026-01-15 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-02 View
- 42025-12-31 View
- 42025-12-29 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|